Gemcitabine-Induced Bullous Acral Erythema

• Autor(a) principal: Pinto-Gouveia, Miguel
• Data de Publicação: 2016
• Outros Autores: Coutinho, Inês, Ramos, Leonor, Brites, Maria Manuel, Cardoso, José Carlos, Tellechea, Óscar, Figueiredo, Américo
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: https://doi.org/10.29021/spdv.74.2.560
• topic: Erythema/chemically induced; Foot Dermatoses/chemically induced; Gemcitabine/adverse effects; Skin Diseases; Vesiculobullous/chemically induced; Dermatopatias Vesiculobolhosas/induzido quimicamente; Dermatoses do Pé/induzido quimicamente; Eritema/ induzido quimicamente; Gemcitabina/efeitos adversos

Chemotherapy-induced acral erythema is characterized by areas of painful erythema affecting predominantly hands and feet, and in severe cases bullous lesions may develop. Gemcitabine is frequently responsible for cutaneous side effects, but these are usually mild and transient. We report a patient under palliative chemotherapy for pancreatic ductal adenocarcinoma with gemcitabine, who presented large bullous lesions on both feet, but of larger size on the left. Histopathology was consistent with acral erythema. The bullous variant of chemotherapy-induced acral eythema is a rare reaction, and although described for structurally similar cytotoxic agents, it has not been reported in association with gemcitabine. In our case, the patient’s medical history of significant peripheral arterial disease may have also played an important role in the overall clinical presentation.